Glufosfamide - Eleison Pharmaceuticals

Drug Profile

Glufosfamide - Eleison Pharmaceuticals

Alternative Names: Beta-D-Glc-IPM; D 19575; Glufosfamide; β-D-Glc-IPM

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Oncology; German Cancer Research Center
  • Developer Baxter Oncology; Eleison Pharmaceuticals; MediBIC; Threshold Pharmaceuticals
  • Class Antineoplastics; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma

Most Recent Events

  • 21 Nov 2017 Eleison Pharmaceuticals and China Oncology Focus agree to co-promote and co-develop glufosfamide in China and other countries of south-east Asia for Pancreatic cancer
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top